Use of psychotropic medications in Sao Paulo Metropolitan Area, Brazil: pattern of healthcare provision to general population

Carregando...
Imagem de Miniatura
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Citação
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, v.24, n.11, p.1207-1214, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose We estimate the proportion of psychotropic medication use (PMU) among adults in Sao Paulo Metropolitan Area, Brazil. We investigated whether socio-demographic factors, comorbidity, and disease severity influence PMU among individuals with psychiatric disorders. Methods Data are from the Sao Paulo Megacity Mental Health Survey, a cross-sectional, population-based study, the Brazilian branch of the World Mental Health Survey Initiative. Trained lay interviewers face-to-face assessed psychiatric disorders and PMU through the Composite International Diagnostic Interview. Respondents were asked about use of healthcare service and prescribed medications for mental disorders in the previous year. Information on PMU was collected for 2935 adult residents in the area and among those with disorders who received treatment. Results Around 6% of respondents reported PMU in the past year: hypnotics or sedatives were used by 3.7% and antidepressants by 3.5%. Among individuals with 12-month disorders, only 14% reported past year PMU. Gender, age, education, income, occupational status, comorbidity, and severity were significant predictors for PMU. Among those with 12-month DSM-IV disorders who obtained treatment in healthcare settings, almost 40% received medication only. Among those treated in specialty mental health service, around 23% received combination of medication and psychotherapy. Conclusion Our study has pointed out that the recent trend of access to mental healthcare in Brazil depicts unmet needs, characterized by a low prevalence of PMU among individuals with psychiatric disorders. Policies that improve appropriate access to prescribed drugs for those most in need are urgent public health priority.
Palavras-chave
pharmacoepidemiology, mental disorders/therapy, psychotropic drugs, mental disorders/epidemiology
Referências
  1. Andrade LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031879
  2. Leon AC, 1997, INT J PSYCHIAT MED, V27, P93
  3. Baldessarini R, 2008, PSYCHIAT SERV, V59, P1175, DOI 10.1176/appi.ps.59.10.1175
  4. Viana MC, 2009, REV BRAS PSIQUIATR, V31, P375, DOI 10.1590/S1516-44462009000400016
  5. Katz SJ, 1998, J GEN INTERN MED, V13, P77, DOI 10.1046/j.1525-1497.1998.00022.x
  6. Beck CA, 2005, CAN J PSYCHIAT, V50, P605
  7. Vorcaro CMR, 2004, INT J SOC PSYCHIATR, V50, P216, DOI 10.1177/0020764004043131
  8. Gasquet I, 2005, ENCEPHALE, V31, P195
  9. Rodrigues MAP, 2006, REV SAUDE PUBL, V40, P107, DOI 10.1590/S0034-89102006000100017
  10. Demyttenaere K, 2008, J AFFECT DISORDERS, V110, P84, DOI 10.1016/j.jad.2008.01.011
  11. MARI JD, 1993, PSYCHOL MED, V23, P467
  12. Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168
  13. Gwynn RC, 2008, PSYCHIAT SERV, V59, P641, DOI 10.1176/appi.ps.59.6.641
  14. Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P55
  15. KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8
  16. Baldoni AO, 2011, REV U VALE RIO VERDE, V9, P78, DOI 10.5892/RUVRV.91.7888
  17. Bruffaerts R, 2005, Rev Med Liege, V60, P181
  18. Codony M, 2007, Actas Esp Psiquiatr, V35 Suppl 2, P29
  19. Grinshpoon Alexander, 2007, Prim Care Companion J Clin Psychiatry, V9, P356
  20. Harkness J., 2008, The WHO world mental health surveys: global perspectives on the epidemiology of mental disorders, P91
  21. IBGE, 2011, CENS DEM POP AN 2000
  22. Kessler RC, 2008, WHO WORLD MENTAL HLT
  23. Quintana MI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062270
  24. Research Triangle Institute SUDAAN, 2002, PROF SOFTW SURV DAT
  25. Tancredi FB, 1979, THESIS
  26. WHO (Collaborating Centre for Drug Statistics Methodology), 2012, GUID ATC CLASS DDD A